United Therapeutics Corporation (UTHR)

United Therapeutics Revenue by Segment

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
Tyvaso	1.71B	1.62B	1.56B	1.45B	1.37B	1.23B	1.13B	1.06B
Tyvaso Growth	25.33%	31.34%	38.18%	36.87%	45.60%	41.32%	41.17%	50.25%
Remodulin	548.30M	538.10M	518.70M	521.50M	501.40M	494.80M	502.20M	485.10M
Remodulin Growth	9.35%	8.75%	3.29%	7.50%	2.35%	-1.08%	1.25%	-4.39%
Orenitram	448.80M	434.30M	410.60M	389.40M	377.40M	359.40M	351.10M	346.60M
Orenitram Growth	18.92%	20.84%	16.95%	12.35%	14.19%	10.55%	9.17%	8.55%
Unituxin	238.50M	238.70M	225.40M	215.60M	208.20M	198.90M	181.40M	176.20M
Unituxin Growth	14.55%	20.01%	24.26%	22.36%	18.03%	8.75%	-7.54%	-14.22%
Adcirca	23.40M	23.80M	25.90M	26.20M	28.00M	28.90M	32.50M	35.90M
Adcirca Growth	-16.43%	-17.65%	-20.31%	-27.02%	-27.84%	-30.02%	-16.67%	-16.32%
Other	16.00M	17.20M	15.60M	-	12.00M	8.30M	8.20M	-
Other Growth	33.33%	107.23%	90.24%	-	90.48%	-39.86%	-	-

Revenue by Geography

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
United States	2.85B	2.74B	2.62B	2.49B	2.37B	2.20B	2.08B	2.00B
United States Growth	19.96%	24.41%	25.96%	24.63%	26.68%	21.39%	19.78%	21.06%
International	146.30M	137.70M	136.30M	129.50M	124.30M	125.30M	124.30M	115.30M
International Growth	17.70%	9.90%	9.65%	12.32%	15.84%	2.54%	0.65%	-17.82%

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.